SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  June 5, 2008

 

EXACT SCIENCES CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

 

 

Registrant’s telephone number, including area code:  (508) 683-1200

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 7.01

Regulation FD Disclosure.

 

On June 5, 2008, EXACT Sciences Corporation (the “Company”) issued a press release, a copy of which is being furnished as Exhibit 99.1 to this Report on Form 8-K.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 8.01

Other Events.

 

Laboratory Corporation of America Holdings (“LabCorp”) has informed the Company that it intends to commercially launch a new laboratory-developed stool-DNA colorectal cancer test in 2008 based on certain rights to which LabCorp has access pursuant to the Company’s exclusive license agreement with LabCorp.  In connection with the foregoing, effective as of June 1, 2008, LabCorp has notified the Company that it has ceased commercially offering PreGen-Plus, the stool-based DNA assay previously marketed by LabCorp for colorectal cancer screening in the average-risk population.

 

Item 9.01		Financial Statements and Exhibits.
	(d)	Exhibits:
		99.1	Press Release issued by the registrant on June 5, 2008, furnished herewith.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

			EXACT Sciences Corporation
June 5, 2008	By:	/s/	Charles R. Carelli, Jr.
			Charles R. Carelli, Jr.
			Senior Vice President, Chief Financial Officer, Treasurer and Secretary

 

3

 

EXHIBIT INDEX

 

Exhibit Number		Description
99.1		Press Release issued by the registrant on June 5, 2008, furnished herewith.

 

4